| SELLNER, L., M. BRUGGEMANN, M. SCHLITT, H. KNECHT, D. HERRMANN, Tomáš REIGL, Adam KREJČÍ, Vojtěch BYSTRÝ, Nikos DARZENTAS, M. RIEGER, S. DIETRICH, T. LUFT, A.D. HO, M. KNEBA and P. DREGER. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. Bone Marrow Transplantation. London: Nature Publishing Group, 2017, vol. 52, No 4, p. 544-551. ISSN 0268-3369. Available from: https://dx.doi.org/10.1038/bmt.2016.305. |
Other formats:
BibTeX
LaTeX
RIS
@article{1411376,
author = {Sellner, L. and Bruggemann, M. and Schlitt, M. and Knecht, H. and Herrmann, D. and Reigl, Tomáš and Krejčí, Adam and Bystrý, Vojtěch and Darzentas, Nikos and Rieger, M. and Dietrich, S. and Luft, T. and Ho, A.D. and Kneba, M. and Dreger, P.},
article_location = {London},
article_number = {4},
doi = {http://dx.doi.org/10.1038/bmt.2016.305},
keywords = {STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; MARROW TRANSPLANTATION; CLINICAL-SIGNIFICANCE; GENE REARRANGEMENTS; ADULT PATIENTS; STANDARD-RISK; CLL3X TRIAL},
language = {eng},
issn = {0268-3369},
journal = {Bone Marrow Transplantation},
title = {GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses},
url = {https://www.nature.com/articles/bmt2016305},
volume = {52},
year = {2017}
}
TY - JOUR
ID - 1411376
AU - Sellner, L. - Bruggemann, M. - Schlitt, M. - Knecht, H. - Herrmann, D. - Reigl, Tomáš - Krejčí, Adam - Bystrý, Vojtěch - Darzentas, Nikos - Rieger, M. - Dietrich, S. - Luft, T. - Ho, A.D. - Kneba, M. - Dreger, P.
PY - 2017
TI - GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses
JF - Bone Marrow Transplantation
VL - 52
IS - 4
SP - 544-551
EP - 544-551
PB - Nature Publishing Group
SN - 02683369
KW - STEM-CELL TRANSPLANTATION
KW - MINIMAL RESIDUAL DISEASE
KW - ACUTE LYMPHOBLASTIC-LEUKEMIA
KW - CHRONIC LYMPHOCYTIC-LEUKEMIA
KW - MARROW TRANSPLANTATION
KW - CLINICAL-SIGNIFICANCE
KW - GENE REARRANGEMENTS
KW - ADULT PATIENTS
KW - STANDARD-RISK
KW - CLL3X TRIAL
UR - https://www.nature.com/articles/bmt2016305
L2 - https://www.nature.com/articles/bmt2016305
N2 - Allogeneic stem cell transplantation (alloSCT) is used for treating patients with T-prolymphocytic leukemia (T-PLL). However, direct evidence of GvL activity in T-PLL is lacking. We correlated minimal residual disease (MRD) kinetics with immune interventions and T-cell receptor (TCR) repertoire diversity alterations in patients after alloSCT for T-PLL. Longitudinal quantitative MRD monitoring was performed by clone-specific real-time PCR of TCR rearrangements (n = 7), and TCR repertoire diversity assessment by nextgeneration sequencing (NGS; n = 3) Although post-transplant immunomodulation (immunosuppression tapering or donor lymphocyte infusions) resulted in significant reduction (>1 log) of MRD levels in 7 of 10 occasions, durable MRD clearance was observed in only two patients. In all three patients analyzed by TCR-NGS, MRD responses were reproducibly associated with a shift from a clonal, T-PLL-driven profile to a polyclonal signature. Novel clonotypes that could explain a clonal GvL effect did not emerge. In conclusion, TCR-based MRD quantification appears to be a suitable tool for monitoring and guiding treatment interventions in T-PLL. The MRD responses to immune modulation observed here provide first molecular evidence for GvL activity in T-PLL which, however, may be often only transient and reliant on a poly-/oligoclonal rather than a monoclonal T-cell response.
ER -
SELLNER, L., M. BRUGGEMANN, M. SCHLITT, H. KNECHT, D. HERRMANN, Tomáš REIGL, Adam KREJČÍ, Vojtěch BYSTRÝ, Nikos DARZENTAS, M. RIEGER, S. DIETRICH, T. LUFT, A.D. HO, M. KNEBA and P. DREGER. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. \textit{Bone Marrow Transplantation}. London: Nature Publishing Group, 2017, vol.~52, No~4, p.~544-551. ISSN~0268-3369. Available from: https://dx.doi.org/10.1038/bmt.2016.305.
|
